Regulation of Krüppel-like factor 6 tumor suppressor activity by acetylation

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9216-9225

  Li, Dan ^a   Yea, Steven ^a   Dolios, Georgia ^a   Martignetti, Joan A ^a   Narla, Goutham ^a   Wang, Rong ^a   Walsh, Martin J ^a   Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE ACETYLTRANSFERASE; KRUPPEL LIKE FACTOR 6 TUMOR SUPPRESSOR PROTEIN; LYSINE; PROTEIN P300; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE; KLF6 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; ONCOPROTEIN; PCAF PROTEIN, HUMAN;

ACETYLATION; ALLELE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE INACTIVATION; GENE LOSS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; METHYLATION; MUTANT; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TRANSACTIVATION; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; BIOSYNTHESIS; CELL STRAIN 3T3; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; PROSTATE TUMOR; TUMOR CELL LINE;

ACETYLATION; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 27144524063     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1040     Document Type: Article

References (60)

1. Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294:2563-6.
2. Ratziu V, Lalazar A, Wong L, et al. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proc Natl Acad Sci U S A 1998;95:9500-5.
3. Turner J, Crossley M. Mammalian Kruppel-like transcription factors: more than just a pretty finger. Trends Biochem Sci 1999;24:236-40.
4. Bieker JJ. Kruppel-like factors: three fingers in many pies. J Biol Chem 2001;276:34355-8.
5. Koritschoner NP, Bocco JL, Panzetta-Dutari GM, Dumur CI, Flury A, Patrito LC. A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene. J Biol Chem 1997;272: 9573-80.
6. Suzuki T, Yamamoto T, Kurabayashi M, Nagai R, Yazaki Y, Horikoshi M. Isolation and initial characterization of GBF, a novel DNA-binding zinc finger protein that binds to the GC-rich binding sites of the HIV-1 promoter. J Biochem (Tokyo) 1998;124:389-95.
7. Kim Y, Ratziu V, Choi SG, et al. Transcriptional activation of transforming growth factor β1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 1998;273:33750-8.
8. Warke VG, Nambiar MP, Krishnan S, et al. Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem 2003;278:14812-9.
9. Kojima S, Hayashi S, Shimokado K, et al. Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-β1 in vascular endothelial cells. Blood 2000;95:1309-16.
10. Inuzuka H, Wakao H, Masuho Y, Muramatsu MA, Tojo H, Nanbu-Wakao R. cDNA cloning and expression analysis of mouse zf9, a Kruppel-like transcription factor gene that is induced by adipogenic hormonal stimulation in 3T3-L1 cells. Biochim Biophys Acta 1999;1447:199-207.
11. Chen C, Hyytinen ER, Sun X, et al. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 2003;162:1349-54.
12. Reeves HL, Narla G, Oginbiyi O, et al. Kruppel-like Factor 6 (KLF6) is a tumor suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 2004;126:1090-103.
13. Chen HK, Liu XQ, Lin J, Chen TY, Feng QS, Zeng YX. Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng 2002;21:1047-50.
14. Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 2003;105:625-9.
15. Kremer-Tal S, Reeves HL, Narla G, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004;40:1047-52.
16. Ito G, Uchiyama M, Kondo M, et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 2004;64:3838-43.
17. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RH, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23.
18. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
19. Okano J, Opitz OG, Nakagawa H, Jenkins TD, Friedman SL, Rustgi AK. The Kruppel-like transcriptional factors Zf9 and GKLF coactivate the human keratin 4 promoter and physically interact. FEES Lett 2000;473:95-100.
20. Botelia LM, Sanchez-Elsner T, Sanz-Rodriguez F, et al, Transcriptional activation of endoglin and transforming growth factor-β signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002;100:4001-10.
21. Barlev NA, Liu L, Chehab NH, et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 2001;8:1243-54.
22. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002;108:475-87.
23. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997;387:823-7.
24. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997;89:1175-84.
25. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 2001;3:667-74.
26. Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci U S A 2000;97:1020-5.
27. Doetzlhofer A, Rotheneder H, Lagger G, et al. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999;19:5504-11.
28. Matsumoto N, Laub F, Aldabe R, et al. Cloning the cDNA for a new human zinc finger protein defines a group of closely related Kruppel-like transcription factors. J Biol Chem 1998;273:28229-37.
29. Zhang W, Kadam S, Emerson BM, Bieker JJ. Site-specific acetylation by p300 or CREB binding protein regulates erythroid Kruppel-like factor transcriptional activity via its interaction with the SWI-SNF complex. Mol Cell Biol 2001;21:2413-22.
30. Scolnick DM, Chehab NH, Stavridi ES, et al. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 1997;57:3693-6.
31. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553-77.
32. Janknecht R, Hunter T. Transcription. A growing coactivator network. Nature 1996;383:22-3.
33. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000;19:1176-9.
34. Shikama N, Lee CW, France S, et al. A novel cofactor for p300 that regulates the p53 response. Mol Cell 1999;4:365-76.
35. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998;396:594-8.
36. Liu L, Scolnick DM, Trievel RC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999;19:1202-9.
37. Lundblad JR, Kwok RP, Laurance ME, Harter ML, Goodman RH. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional coactivator CBP. Nature 1995;374:85-8.
38. Jiang H, Lu H, Schiltz RL, et al. PCAF interacts with tax and stimulates tax transactivation in a histone acetyltransferase-independent manner. Mol Cell Biol 1999;19:8136-45.
39. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 1998;95: 2302-6.
40. Nishio H, Walsh MJ. CCAAT displacement protein/cut homolog recruits G9a histone lysine methyltransferase to repress transcription. Proc Natl Acad Sci U S A 2004;101:11257-62.
41. Cartel AL, Tyner AL. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999;246:280-9.
42. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000;19:662-71.
43. Kimmelman AC, Qiao RF, Narla G, et al. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 2004;23:5077-83.
44. Wang SP, Chen XP, Qiu FZ. A candidate tumor suppressor gene mutated in primary hepatocellular carcinoma: Kruppel-like factor 6. Zhonghua Wai Ke Za Zhi 2004;42:1258-61.
45. Fang JY, Lu YY. Effects of histone acetylation and DNA methylation on p21(WAF1) regulation. World J Gastroenterol 2002;8:400-5.
46. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999;9:171-4.
47. Benzeno S, Narla G, Allina J, et al. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 2004;64: 3885-91.
48. Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-β. J Biol Chem 2000;275: 29244-56.
49. Xiao H, Hasegawa T, Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem 1999;73:291-302.
50. Mujtaba S, He Y, Zeng L, et al. Structural mechanism of the bromodomain of the coactivatoi CBP in p53 transcriptional activation. Mol Cell 2004;13:251-63.
51. Wang YH, Tsay YG, Tan BC, Lo WY, Lee SC. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem 2003;278:25568-76.
52. Haupt Y, Robles AI, Prives C, Rotter V. Deconstruction of p53 functions and regulation. Oncogene 2002;21:8223-31.
53. Minamoto T, Buschmann T, Habelhah H, et al. Distinct pattern of p53 phosphorylation in human tumors. Oncogene 2001;20:3341-7.
54. Nakaimira S, Roth JA, Mukhopadhyay T. Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells. Oncogene 2002;21:2605-10.
55. 18 phosphorylation in regulating p53 responses. J Biol Chem 2003;278:41028-33.
56. Nguyen DX, Baglia LA, Huang SM, Baker CM, McCance DJ. Acetylation regulates the differentiation-specific functions of the retinoblastoma protein. EMBO J 2004;23:1609-18.
57. Puri PL, Sartorelli V, Yang XJ, et al. Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1997;1:35-45.
58. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 2002;21:6539-48.
59. Matsumura T, Suzuki T, Aizawa K, et al. The deacetylase HDAC1 negatively regulates the cardiovascular transcription factor Kruppel-like factor 5 through direct interaction. J Biol Chem 2005;280:12123-9.
60. Song CZ, Keller K, Chen Y, Stamatoyannopoulos G. Functional interplay between CBP and PCAF in acetylation and regulation of transcription factor KLF13 activity. J Mol Biol 2003;329:207-15.